This section summarises published information regarding the concepts in managing invasive fungal infections in children, with specific reference to Aspergillus.
Broadly there are two sections comprising diagnosis and treatment regimes. The data here are sourced and summarised from a series of publications in Clinical Microbiology Infect. 16(9), 1319-53, 2010 by Groll et al, Walsh et al, Dornbusch et al& all these references are more comprehensive than the data compiled here and we recommend referral to the original publications for further detail.
To view any links to publication please register your name with the site here.
Children and in particular neonates and young infants, are a unique patient population, particularly with respect to fungal infections.
Invasive fungal infections are dificult to diagnose - but response to treatment and outcome is dependent on a prompt initial diagnosis and the initiation of treatment.
Epidemiology and Clinical Trials
The epidemiology, presentation and pre-disposing conditions show significant differences in paediatric versus adult patients.
The use of antifungal agents in this patient group requires an understanding of pharmacodynamics and safety issues - which accumulating evidence suggests can not always be empirically derived from data collected on usage in adult groups.
Many antifungal clinical trials have previously excluded paediatric groups so there is a lack of trials of large cohorts- but there is data in the literature for smaller cohorts of paediatric patients- for various antifungal treatments.
New antifungals are continually going into trials - however the need for evaluation in paediatric patients is great.
This website specialises in Aspergillus infections - but the lack of paediatric data has meant that we have included data for other types of fungal infections - where it may be useful.